Normalization against the relevant values of -actin was then carried out
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
While a UDS can be an important tool, these screens can be prone to error, with potentially devastating consequences
8 9 2 Weighing surgery versus GLP-1s For people with significant obesity, GLP-1 medications and bariatric surgery are sometimes framed as competing options: Pick one or the other
It comes as little surprise, then, to learn that retailers are indeed seeing the GLP-1-inspired effects of this trend in both foot traffic and sales figures
PMC 3549305
